Tumor Cell Metabolism: Cancer's Achilles' Heel is a research paper published in Cancer Cell (2008). On theSindex it has a DataRank of 1.2. It has been cited 2,313 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.2
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →FWCI
41.04
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 1 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 2 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 2 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 3 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 3 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 4 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 5 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 4 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 5 of Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
Additional file 1 of Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy
Additional file 1 of Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy
Additional file 1 of A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma
Additional file 1 of A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma
Additional file 2 of Highly-purified rapidly expanding clones, RECs, are superior for functional-mitochondrial transfer
Additional file 2 of Highly-purified rapidly expanding clones, RECs, are superior for functional-mitochondrial transfer
Additional file 1 of The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation
Additional file 1 of The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation
Additional file 1 of Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization
Additional file 1 of Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization